The main aim of this research was to evaluate the toxicokinetic characteristics of fusarenon-X (FX) and its metabolite, nivalenol (NIV), in goats. The amounts of FX and NIV in post-mitochondrial (S-9), microsomal and cytosolic fractions of diverse tissues of the goat were also investigated. FX was intravenously (iv) or orally (po) administered to goats at dosages of 0.25 and 1 mg/kg bw, respectively. The concentrations of FX and NIV in plasma, feces and urine were quantified by liquid chromatography tandem-mass spectrometry (LC-ESI-MS/MS). The concentrations of FX in plasma were quantified up to 8 h with both routes of administration. A large amount of NIV (metabolite) was quantifiable in plasma, urine and feces after both administrations. The C max value of FX was 413.39 ± 206.84 ng/ml after po administration. The elimination half-life values were 1.64 ± 0.32 h and 4.69 ± 1.25 h after iv and po administration, respectively. In vitro experiments showed that the conversion FXto-NIV mainly occurs in the liver microsomal fraction. This is the first study that evaluates the fate and metabolism of FX in ruminant species.
Introduction
Among the trichothecenes discovered to date, deoxynivalenol (DON), T-2 toxin (T-2), diacetoxyscirpenol (DAS) and Fusarenon-X (FX) are known to contaminate feed globally (Pittet, 1998) . Trichothecenes have been classified into A, B, C, and D types. Type A and B trichothecene mycotoxins have a wide range of toxic effects on farm animals and humans (WHO, 1990) . In farm animals, they can cause diarrhea, feed refusal, weight loss, decreased production performance, immune suppression and residues in animal food products (Eriksen and Pettersson, 2004) .
FX, a type B trichothecene mycotoxin, is mainly produced by the Fusarium fungi, which naturally occurs in agricultural commodities such as cereal and cereal products, including wheat, barley, corn, rye, oats, maize and multigrain (Broekaert et al., 2015; Cavalier et al., 2005; Juan et al., 2013; Placinta et al., 1999) . FX was first isolated from Fusarium nivale strain Fn-2B, its production depends on many factors, including the substrate, temperature and humidity (Cavalier et al., 2005; Juan et al., 2013) . Although deoxynivalenol (DON) is the most commonly found globally, the derived products, particularly breakfast cereals and bread, are susceptible to FX contamination, and are very important in the human diet including in baby foods (Placinta et al., 1999; Juan et al., 2013; Yzar and Omurtag, 2008) . There are some reports that FX has been frequently detected along with DON and nivalenol (NIV) (IARC, 1993) .
FX predominantly occurs in temperate regions of Europe and Asia, because these geographical zones are suitable for Fusarium growth and FX production.
FX has been characterized as more potently toxic than the other members of type B trichothecene mycotoxins (IARC, 1993) . FX can evoke a ribotoxic stress response, which inhibits protein and DNA synthesis in eukaryotic cells (Aupanan et al., 2017) . FX has been reported to induce adverse health effects, particularly apoptosis, in organs containing actively dividing cells such as the small intestine, thymus, spleen, bone marrow, testes, and in cells such as reticulocytes and mitogen-stimulated human lymphocytes; these effects have also been observed after exposure to other trichothecenes (Forsell and Pestka, 1985; Miura et al., 1998; Poapolathep et al., 2001 Poapolathep et al., , 2002 . Furthermore, FX dose-dependently encourages DNA strand breakage of both dividing cells and differentiated Caco-2 cells (Alassane- Kpembi et al., 2013 has been reported to induce apoptosis in developing mouse brain, thymus, Peyer's patches, spleen and human jurkat T cells (Aupanan et al., 2015; Sutjarit et al., 2014) .
The European Commission (EC) has regulated acceptable levels of trichothecene mycotoxins in cereal grains, flours, and cereal-based products intended for human and animal consumption (Gareis et al., 2003; EC, 2006) but the limited available information prevents establishing a regulatory limit for FX (Gareis et al., 2003) . Nowadays, the European Food Safety Authority Panel on Contaminants in the Food Chain (CONTAM) establishes the tolerable daily intake of NIV as 1.2 mg/kg bw/day based on a lowest-observed-adverse-effect of 0.7 mg/kg bw/day found in long-term dietary studies in mice (EFSA, 2013) .
Toxicokinetic profiles of FX and its metabolite NIV have been reported in mice, broiler chickens, ducks and piglets (Poapolathep et al., 2003 (Poapolathep et al., , 2004 Saengtienchai et al., 2014) but to the best of the authors' knowledge no data exist on its toxicokinetics in ruminants. Tremendous variations in the species specific toxicokinetic profiles of FX have been observed. Further information on the toxicokinetics of FX is also needed to evaluate possible differences in toxicity between monogastric animals and ruminants. Therefore, this study aimed to evaluate the toxicokinetic characteristics of FX and its metabolite NIV in goats after intravenous (iv) and oral (po) administrations. The amounts of FX and NIV in post-mitochondrial (S-9), microsomal and cytosolic fractions of diverse tissues of the goat were also investigated.
Materials and methods

Animals
Eleven 9-week-old male goats (average weight 7.74 ± 0.44 kg) were purchased from a commercial goat farm (Saraburi Thailand). The experimental animals were housed at the Laboratory Animal Facility, Bureau of Veterinary Biologics, Department of Livestock, Nakhon Ratchasima province, Thailand. Animals were acclimatized to the environment for 1 week prior to the commencement of the study. The animals were fed with dried pangola grass and water ad libitum. All experimental procedures on animals were ethically approved by the Animal Ethics Research Committee of the Faculty of Veterinary Medicine, Kasetsart University.
Chemicals and reagents
Standard FX and NIV were purchased from Wako Pure Chemical Industries Ltd. (Kyoto, Japan). Other analytical grade reagents and chemicals were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Purified water was produced using the Milli-Q water purification system from Millipore, Inc (Bedford, MA, USA). The solutions for iv and po administrations were prepared in one batch at a concentration of 2 mg/ml by dissolving standard FX in 0.01 M phosphate buffer saline pH 7.4 containing 10% (v/v) dimethyl sulfoxide (DMSO).
Toxicokinetic study
Ten goats were randomly divided into two groups (n = 5). After overnight fasting, each group was administered FX iv (into the right jugular vein) or po at a dosage of 0.25 or 1.0 mg/kg bw, respectively. Blood samples (2.5-3.0 ml) were collected from the left jugular vein of each goat with heparinized syringes at 0, 5, 15 and 30 min and 1, 2, 4, 6, 8, 12, 24, 48 , and 72 h, whereas the urine and feces were collected at 0-2 h, 2-4 h, 4-8 h, 8-12 h, 12-24 h and 24-48 h after FX administration. The urine and faecal samples were immediately collected from the individual animals. The plasma was separated by centrifugation at 1968 g for 15 min and immediately frozen at −20°C until analyzed. The urine and faecal samples were also stored at −20°C until analyzed.
Extraction and clean up
The extraction method of FX and NIV in plasma, urine and feces was based on a previously published method (Poapolathep et al., 2008) . Briefly, 1 ml of goat plasma or urine, or 5 g of feces were extracted with 3 ml of acetonitrile (ACN)-water (3/1, v/v). Two g of ammonium sulfate were added, and shaken for 30 s by a vortex mixer. The ACN fraction was separated by centrifugation at 1968 g for 15 min. The supernatant was collected in the glass tube. These extraction steps were then repeated for 2 additional cycles. The supernatant fractions were combined and purified using the solid phase extraction cartridge (C18 Sep-pak silica cartridge) (Waters Corp., Milford, MS, USA) as described previously (Poapolathep et al., 2008) . The eluate was completely evaporated under a nitrogen stream at 40°C on a heating block. The residue was reconstituted with 500 μl of methanol-water (1:4) v/v with 5 mM ammonium acetate, and injected onto a 0.22 μm syringed filter (Sartorius AG, Goettingen, Germany) before being analyzed by liquid chromatography tandem-mass spectrometry (LC-MS/MS).
Preparation of postmitochondrial (S-9), microsomal and cytosolic fractions
In order to study the metabolites of FX, one 9-week-old male goat was sacrificed with thiopentone sodium at a dosage of 20 mg/kg of bw by iv administration. Various tissues including the liver, kidney, heart, lung, muscle, rumen, reticulum, omasum, abomasum, duodenum, jejunum, ilium, colon and rectum were immediately collected and frozen in liquid nitrogen and stored at −80°C until assayed. The postmitochondrial (S-9), microsomal and cytosolic fractions were prepared as described (Esaki and Kumagai, 2002; Poapolathep et al., 2008) . Briefly, a portion of the thawed tissue sample was cut into small pieces using scissors and homogenized in a motor driven glass homogenizer. The homogenates were centrifuged at 10,000 rpm for 10 min to separate the supernatant designated as the S-9 fraction. S-9 fraction was then centrifuged at 105,000 × g for 1 h to collect the cytosolic fraction. The pellet was resuspended and recentrifuged at 105,000 × g. Supernatant was discarded and the microsomal fraction was resuspended in 20 mM Tris buffer pH 7.4 containing 1 mM ethylene diamine tetraacetic acid (EDTA) and 0.25 M sucrose. All preparation procedures were performed on ice and all sample fractions were kept at −80°C until analyzed.
Protein assay
Protein concentrations in S-9, microsomal, and cytosolic fractions were determined as described by Esaki and Kumagais (Esaki and Kumagai, 2002) . In brief, 2 ml of S-9, microsomal, or cytosolic fractions from each tissue were added to 5 ml of the dye reagent: water, 1:4 v/v, mixture. The samples were then incubated at room temperature for 5 min and measured spectrophotometrically at 595 nm using a GENESYS TM 20 spectrophotometer (Thermo Fisher Scientific, Washington, USA). Bovine serum albumin (Bio-Rad Protein Assay, Bio-Rad Lab, CA) was used as the standard for the protein assay.
2.7. Determination of S-9, microsomal and cytosolic activity to form NIV Conversion of FX by S-9, microsomal and cytosolic activities was performed according to a published method (Esaki and Kumagai, 2002) . In brief, 1 mg protein of S-9, microsomal and cytosolic fractions was pre-incubated at 37°C in an incubation buffer consisting of potassium phosphate buffer (100 mM, pH 7.4), G-6-P (5.6 mM), NADPH (2 mM) and G-6-P dehydrogenase (0.5 unit). After pre-incubation for 5 min, FX (5 mg/10 ml of methanol) 5 μg of FX in 10 μl of methanol was added and the mixtures were continuously incubated whilst being shaken for 0, 15, 30, 45 and 60 min. The reaction was terminated by adding an equal volume of ice-cold chloroform, followed by vigorous mixing and centrifugation at 5000 rpm for 10 min at 4°C. The incubation mixtures were extracted with the mixture of ACN and water solution described above. The residue was reconstituted with the mobile phase solution, and injected onto a 0.22 μm syringed filter (Sartorius AG, Goettingen, Germany) before being analyzed by LC-MS/MS.
LC parameters
LC analysis was performed using an Agilent 1260 Infinity (Agilent Technologies, Waldbronn, Germany) consisting of a binary pump, a vacuum degasser, a column oven and an auto sampler. The chromatographic separation was performed on a ZORBAX Eclipse Plus Rapid Resolution HT (RRHT) C18 column (4.6 × 50 mm, 1.8 μm particle size, Agilent Technologies) with guard column (4.6 × 5 mm, 1.8 μm particle size, Agilent Technologies). The column was maintained at 40°C. The mobile phase consisted of 5 mM ammonium acetate solution (mobile phase A) and methanol (mobile phase B). The gradient program of the mobile phase was as follows: 0-1.0 min, 90% mobile phase A; 1.0-5.0 min, from 90 to 5% mobile phase A; 5-10 min, 5% mobile phase A; 10-11 min, from 5 to 90% mobile phase A; 11-15 min, 90% mobile phase A. The mobile phase solution was filtered through a 0.22 μm membrane and ultrasonically degassed prior to application. The flow rate was 0.4 ml/min, while the injection volume was 10 μl. The temperature of the autosampler was set at 4°C.
MS parameters
A triple quadrupole mass spectrometer was used (6460 triple, Agilent Technologies), this was equipped with an electrospray ionization source operated in positive ion modes (ESI+) under the multiple reaction monitoring mode (MRM) . The ionization source parameters were optimized as follows: capillary voltage: 3500 V; gas temperature: 320°C; gas flow: 8 l/min, and nebulizer: 50 psi. Under these conditions, 
Method validation
Validation of the LC-MS/MS method for FX and NIV was performed to assess the efficiency of this analytical method by investigating the recovery, repeatability, linear working range, limit of detection (LOD), limit of quantification (LOQ), accuracy, precision and matrix effects in accordance with the guidelines on bioanalytical method validation EMEA/CHMP/EWP/2012. The linearity of an analytical procedure is its ability (within a given range) to produce test results that are directly proportional to the concentration (amount) of analyte in the sample. Linear regression analysis was conducted for the FX and NIV standards under the optimized LC-MS/MS conditions. Linearity of the regression curve was assessed on the basis of the residual plot, the fit test and the back-calculation. Recovery, accuracy (%RE) and precision (repeatability, expressed as relative standard deviation (RSD) in %) were determined within-day by analyzing seven replicates containing FX and NIV at three different quality control (QC) levels (5, 50 and 250 ng/ml). The inter-day precisions were determined by analyzing QC samples on five different days (one batch per day). The calibration standard concentrations were prepared in three replicates by spiking the working standard solution into blank samples to yield final concentrations of 2.5 to 1000 ng/ml. The matrix effects were determined for tested matrices by spiking blank plasma, urine and feces. The recovery, LOD, LOQ, accuracy and precision were assessed. The LOD and LOQ of the method were evaluated as the signal versus noise value (S/N) of 3:1 and 10:1, respectively.
Toxicokinetic parameters calculations
The concentrations of FX and NIV in experimental goats vs time were described by a non-compartmental model using WinNonlin software (version 5.3.1). C p 0 was the peak concentration at the initial time,
C max was peak plasma concentration, T max was time at peak plasma concentration, AUC was the area under the curve, V d was the volume of distribution, t 1/2λ was the elimination half-life, Cl was the plasma clearance, MRT was the mean residence time, Vd ss was the volume of distribution at steady state. The oral bioavailability (F) was calculated using the following equation:
Statistical analysis
Toxicokinetic variables were evaluated using the student's t-test to determine statistically significant differences between the treatment groups (iv vs po). Both toxicokinetic parameters and toxin (FX and NIV) plasma concentrations are presented as means ± SD (normality tested by Shapiro-Wilk test). All analyses were conducted using GraphPad InStat (GraphPad Software, La Jolla, CA, USA). In all experiments, differences were considered significant with a p < 0.05.
Results
Method validation and quality assurance
Regarding FX and NIV detection, the LC-MS/MS method used in this study showed linearity range, intra-day and inter-day precision, and accuracy for quantification of FX and NIV within the limits requested by the EMA (2012). Linearity of the calibration curves for plasma, urine and feces matrices, expressed as the determination coefficients (R 2 ), gave values that were all above 0.998. The method validation parameters are shown in Table 1 .
Toxicokinetic study
Both FX and NIV were detectable in the plasma of goats following single iv or po administration. The semilogarithmic plots of the mean ( ± SD) plasma concentration-time curve of FX and NIV at a dosage of 0.25 and 1 mg/kg bw in goats following iv and po administrations are shown in Fig. 1a and b . FX was quantifiable from 5 min to 8 h while NIV was quantifiable from 5 min to 48 h, after iv administration of FX. After oral administration of FX, FX was quantifiable from 5 min to 8 h whereas, NIV was quantifiable from 5 min to 24 h. The mean plasma vs time curve profiles showed a lower concentration of NIV after po as compared to iv administration. This is also reflected by the AUC values for iv vs po, reporting a F% value of FX of about 15.81%. The toxicokinetic parameters are shown in Table 2 . The toxicokinetic parameters although variable among the animals, were however normally distributed (Shapiro-Wilk test) and reported as mean ± SD. This variability is common in farm animals when not inbreed subjects are used (Lee et al., 2017; De Vito et al., 2018; Kim et al., 2018) . Following iv administration, the value for the t 1/2λ of FX (1.64 ± 0.32 h) was shorter than that obtained after po administration (4.69 ± 1.25 h). The Cl value of FX was low (310.98 ± 90.60 ml/h/kg) while the V d was reasonably wide (730.10 ± 257.40 ml/kg). The AUC of NIV was higher than FX both in iv and po administrations. The pharmacokinetic parameters are shown in Table 2 .
Urine and feces excretion
In urine, FX and NIV were quantified in urine after iv administration whereas, after po administration only NIV was quantifiable. In feces, a large amount of NIV was quantifiable after po administration of FX in goats (Table 3) .
Metabolic conversion of FX in S-9, microsomal and cytosolic fractions
To investigate the tissues that contribute to the metabolism of FX into NIV in goats, FX was incubated with S-9, microsomal and cytosolic fractions of different tissues (liver, kidney, heart, lung, muscle, rumen, reticulum, omasum, abomasum, duodenum, jejunum, ilium, colon and rectum) for 15, 30, 45 and 60 min. The results showed that the biotransformation of FX into NIV mainly occurred in the microsomal fraction of liver. The highest activity was 80.8% at 60 min after incubation (Fig. 2a) .The biotransformation of FX to NIV also occurred in the microsomal fraction of the kidney and lung although at lower rate, but no conversion was found in the S-9 and cytosolic fractions (Fig. 2a) . Fig. 2b shows the biotransformation of FX to NIV in the stomach, including rumen, reticulum, omasum and abomasum of goats. The biotransformation was detected in the S-9, microsomal and cytosolic fractions of goat stomach, and the highest activity was shown in the microsomal fractions. Among intestinal tissues, including duodenum, jejunum, ileum, colon, and rectum (Fig. 2c) , the highest activity was shown to be 24.5% at 60 min after incubation in the microsomal fraction of the jejunum. The data for the metabolism of FX into NIV in various tissues of goats are shown in Fig. 2. 
Discussion
The results of this study revealed that FX is rapidly absorbed into the systemic circulation after po administration. A large proportion of NIV was rapidly quantified in the goat, indeed the plasma concentration ratio FX/NIV was already less than one 5 min after iv and po FX administration. NIV was quantified in the plasma from 5 min to 24 h after oral administration of FX, indicating FX was absorbed and metabolized rapidly. These results are also consistent with previous research, showing that FX was rapidly transformed into NIV in liver of mice, broiler chickens, ducks and piglets (Poapolathep et al., 2003 (Poapolathep et al., , 2008 Saengtienchai et al., 2014) . Indeed FX was rapidly absorbed after po administration (Tmax = 0.08 h) and the oral bioavailability was 15.81%. The oral bioavailability of FX in goats was lower than in piglets (74.4%) similar to ducks (19.4%) (Poapolathep et al., 2008; Saengtienchai et al., 2014) , but higher than in broilers (9.8%) (Poapolathep et al., 2008) . The present study demonstrated that the elimination half-life value (t 1/2λ ) was longer in the po (4.69 ± 1.25 h) group than in the iv group (1.64 ± 0.32 h). This might be due to a flip flop effect already described for NIV in broilers (Kongkapan et al., 2016) . On the other hand, the t 1/2λ of NIV obtained in the po group (7.96 ± 2.99 h) was shorter than in the iv group (22.85 ± 4.62 h) after FX administration in goats. This might be due to inhibition of the metabolic enzyme as a result of the sudden high FX plasma concentration that takes place in the IV group (Wen et al., 2016) . This parameter was shorter in goats than that reported in piglets (1.71 h; Table 1 Precision (RSD%), accuracy (%RE) and recovery (%R) of fusarenon-X (FX) and nivalenol (NIV) in biological matrices of goats.
Analyte
Matrice Concentration of QC sample (ng/ml or ng/g) Precision (%RSD) Accuracy (%RE) Recovery ± SD LOD LOQ Intra-day (n = 7)
Inter-day (n = 21) Intra-day (n = 7)
Inter-day (n = 21) (ng/ml or ng/g) (ng/ml or ng/g) Fig. 1 . Mean values ( ± SD) of fusarenon-X (□) and nivalenol (•) concentration in plasma goats at dosages of 0.25 and 1 mg/kg bw of fusarenon-X; a) intravenous administration, and b) oral administration (n = 5). Saengtienchai et al., 2014) , ducks (2.1 h; Poapolathep et al., 2008) but was longer than that in broilers (1.2 h; Poapolathep et al., 2008) after iv administration of FX. The Cl value was 310.98 ± 90.60 ml h/kg after iv administration of FX in goats. This value was greater than that reported in broiler chickens (113.57 ± 18.95 ml h/kg) but similar to that reported in ducks (331.98 ± 66.38 ml h/kg). This might indicate that FX is more efficiently cleared in ducks and goats compared to broiler chickens. Following po administration, the maximum plasma concentration (Cmax) of FX (413.39 ± 206.84 ng/ml) was reached at the time of maximum concentration (Tmax), 0.08 h. The rather low plasma concentration of FX after po administration is indicative off all of the phenomena that might lower the amount of FX that reaches the systemic circulation. These include GI tract microbial activity absorption process from the gut lumen into the intestinal tissue, and metabolism by all of the tissues through which FX must pass to get to the systemic circulation: intestinal tissue, blood capillaries, and the liver (first-pass effect). All together, these likely processes produce a low oral bioavailability (15.8%) of FX. However, a large proportion of NIV was detectable in goat plasma after po administration of FX. These findings might indicate that FX was in fact, efficiently absorbed in the gastrointestinal tract, and it was metabolized to NIV in liver of goats. In urine and feces, a large proportion of NIV was detectable after iv and po administration of FX in goats. These findings suggest that FX is excreted largely as NIV in the urine and feces of goats. The results also are consistent with previous investigations of FX in monogastric animals including, mice, broilers, ducks and piglets, which showed that a large proportion of FX was changed into NIV following FX administration (Poapolathep et al., 2003 (Poapolathep et al., , 2008 Saengtienchai et al., 2014) . However, NIV has been reported to be metabolized to a de-epoxidated form (deepoxynivalenol) by microorganisms in gastrointestinal tract (Wu et al., 2010) but, a de-epoxyidated form was not investigated in this study. Using the assumption that trichothecenes undergo a variety of different metabolic reactions including hydrolysis to split off side groups, hydroxylation and de-epoxidation, the data from the present study suggest a higher efficiency of microsomal enzymes in the liver, compared to other tissues of goats. This also indicated the liver as the likely major site of the FX-to-NIV metabolism in goats. The intestinal microflora is important for the biotransformation of trichothecenes. The presence or absence of particular intestinal microflora species can influence the extent to which an animal is sensitive to NIV, because the epoxidated products were shown to be less toxic than parental molecules. In previous studies, its metabolite NIV was observed in in vitro liver microsomes and S-9 fractions from broilers, ducks, and piglets (Poapolathep et al., 2003 , Saengtienchai et al., 2014 . The current study produced consistent results for FX-to-NIV metabolism. It is possible that liver microsomal fractions of goats have a high capacity for FX biotransformation. The more active metabolism of goats compared other animals is well known (Toutain et al., 2010) . This is linked to their respective feeding behaviour where goats are natural browsers. When eating plants, they preferentially eat the most nutritious part available but will also eat the portions containing many toxic alkaloids that need to be metabolized by a hepatic first pass effect. The highest capacity of FX-to-NIV biotransformation in microsomal fractions was found in the jejunum (25%, among intestinal part) and rumen (3%, among stomach part) of goats. However, it has been reported that ruminants have a high ruminal capacity for biotransforming some Table 2 Mean ± SD value of the toxicokinetic parameters of fusarenon-X (FX) and nivalenol (NIV) following iv and po administration at a dosage of 0.25 and 1 mg/kg bw, respectively in goats (n = 5). Note: t 1/2λ = elimination half-life; Kel = elimination rate constant; T max = time at maximum concentration; C max = the maximum concentration; C p 0 = plasma concentration at initial time; AUC last = area under the curve from zero to 24 h; AUC inf = area under the curve from zero to the last, V d = volume of distribution, CL = clearance; MRT = mean residence time; V dss = volume of distribution at steady state; F = oral bioavailability. § This data is divided for bioavailability when calculated for the po administration.
Table 3
Mean ± SD values of fusarenon-X (FX) and nivalenol (NIV) in urine and feces at dosages of 0.25 and 1.0 mg/kg bw after iv and po administrations of FX in goats (n = 5 per group). mycotoxins to less toxic metabolites (Muller et al., 1998) , microbes transform mycotoxins in the intestinal tract of animals prior to absorption (Schatzmayr et al., 2006; Escriva et al., 2015) and in vivo biotransformation might be larger.
Conclusions
In conclusion, FX is absorbed from the gastrointestinal tract with a relatively low bioavailability in goats. The liver is the organ responsible for the FX-to-NIV biotransformation. FX can be excreted mainly as NIV in the feces of goats after p.o. administration of FX, whereas it can be excreted mainly in urine after iv administration. The results obtained in this study contribute to the knowledge of toxicokinetic behaviour of FX in the goat. However, a depoxidated form as de-epoxynivalenol and the other modified forms should be further investigated.
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